Brad L. Stewart, chairman, CEO and president, is responsible for global commercial operations, corporate strategy and business development. An experienced senior executive, Mr. Stewart maintains a record of success in many specialty-areas of the life sciences industry including: biotech; pharmaceuticals; orphan drugs; and diagnostics.

 

His accomplishments include the establishment and leadership of a successful U.S. business for a European pharmaceutical company; growth and diversification of an orphan drug company; strategic restructuring of the North American business unit of a global pharmaceutical company; development and management of joint ventures, including a multi-million dollar global pharmaceutical venture; creating an operational improvement business within a major global diagnostics company; and extensive management consulting and corporate strategy assignments.

 

Mr. Stewart is a graduate of the University of Florida.

Mr. Sandberg has played a principal role in starting and building a number of medical diagnostic companies including that of founder, chairman, chief executive officer and chief financial officer of DIANON Systems Inc., a publicly traded oncology marketing and database company; chairman and CFO of Lifecodes Corporation, a privately-owned pioneer in DNA testing technology; CFO and member of the board of directors of Matritech Inc., a publicly-traded biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers; CFO and member of the board of directors of Critical Diagnostics Inc., a privately-held cardiac diagnostic company commercializing new technology licensed from the Brigham and Women’s Hospital in Boston; and chairman of the board of Oxford Immunotec, Ltd., a privately-held English diagnostic company focusing on tuberculosis.

Gregory Shearer has spent most of his 25 years in the venture capital and investment banking industries focused exclusively on medical technology.  He founded Channel Medical Partners, a private equity fund dedicated to the medical technology industry.  That firm’s record of success demonstrates his ability to recognize and leverage opportunities to generate superior returns for co-investors, limited partners and management teams.

Prior to founding Channel, Mr. Shearer served as a managing director at Jefferies & Company Inc. and Vector Securities International Inc., with senior responsibility for companies in the medical technology industry.  Mr. Shearer also worked with The First Bos­ton Corporation; Kidder, Peabody & Co. Incorporated; and Morgan Stanley & Co., Incorporated.  He serves on the board of directors of several private medical technology companies in the Channel Medical Partners investment portfolio; and has served on the board of Bethel New Life, and as president of the Centre College Alum­ni Association.

Mr. Shearer received a bachelor’s degree from Centre College and master of business administration from the University of Chicago, Graduate School of Business.

An entrepreneur and practicing physician, Dr. Stephen Bloch possesses unique insight to challenges and opportunities within the health care industry. Medical, academic and research experience guide his investments in biopharmaceuticals, medical devices and diagnostics and health care infrastructure.

Dr. Bloch, general partner at Canaan Partners, led Canaan’s investments in Amicus Therapeutics (FOLD), a clinical-stage biopharmaceutical company and in addition to Cylex, serves as a director of Advanced BioHealing, Liquidia, Marinus Pharmaceuticals and Viacor.

He founded Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services.  He co-founded OmniSonics Medical Technologies and TeleRad, a teleradiology services company; and advised the Arthur D. Little firm on pharmaceuticals and medical devices.

Dr. Bloch received medical training at Massachusetts General Hospital/Harvard Medical School and Lenox Hill Hospital/Cornell Medical School.  He earned a medical degree from the University of Rochester, a master’s degree in the history of science and public policy from Harvard University and a bachelor’s degree from Dartmouth College.  In 2002, he was named a Ewing Marion Kauffman Fellow.

A 20 year veteran of the venture industry, Joseph Falkenstein is experienced in all aspects of the venture process. Mr. Falkenstein co-founded NJTC Venture Fund in 2000, after a successful career as a lead partner in the technology and venture capital practice of Andersen in Philadelphia.  He has significant expertise in finance and capital formation, business strategy and performance optimization.

At NJTC Ventures, Mr. Falkenstein directs startup and early-stage venture capital investments: actively partnering with entrepreneurs to build unique, leading-edge businesses primarily in Medtech and technology-enabled services.

Mr. Falkenstein sits on the boards of Archive Systems, Power Survey Corp, Sword Diagnostics, V12 Group and Cylex, Inc.  He also serves on the boards of the New Jersey Technology Council, Ben Franklin Technology Partners and is a former director of the Mid-Atlantic Capital Alliance.  Mr. Falkenstein is a certified public accountant and a graduate of Temple University.

Anupendra Sharma is partner at Siemens Venture Capital investing in healthcare devices, diagnostics, software and services. He is an investor in BioImagene, China Diagnostics and Cylex™.

Prior to Siemens Venture Capital, Mr. Sharma helped companies go public and raise capital, completing $5 billion in M&A transactions at JPMorgan, Salomon Smith Barney and Siemens. He worked in strategy consulting for McKinsey London and product development finance for Ford Europe, where he was a member of the team that established Ford in China and India.

Mr. Sharma founded several organizations including Mobile Medics, named the “Most Innovative Social Venture of 2006” by the Global Social Venture Competition. Mobile Medics addressed the “last-mile” problem for global rural healthcare and was the subject of a Japan Broadcasting Corporation documentary. Other projects include The Leadership Program at the Center for Entrepreneurial Leadership, BITS Pilani, India; Peking University's Venture Capital Association; and Massachusetts Life Sciences Startup Initiative in Boston.

Mr. Sharma holds a master of business administration from Cornell University, a master of science in accounting and finance from Manchester Business School, a master of science in economics and a bachelor’s degree in instrumentation engineering from BITS Pilani.

Simon Meier is the investment director of the Roche Venture Fund at F. Hoffman-La Roche in Basel, Switzerland.  He was previously head of investment management at GSL (Galli, Schneider and Lehner).

Roche Venture Fund supports development of innovative technologies and medicines with investments in early stage biotech and diagnostics companies. Based in Basel, Switzerland, the Roche Venture Fund, with a portfolio of over 25 companies in 10 countries, is constantly seeking investment opportunities with innovative companies.

Mr. Meier was educated at Universität St. Gallen-Hochschule fϋr Wirtschafts - , Rechts- und Sozialwissenschaften.

As a managing director at First Analysis, Dr. Marshbanks coordinates investment and research activities in the chemistry-enabled sector, specializing in selected areas of life science and advanced materials.

Prior to joining First Analysis in 1999, Dr. Marshbanks worked in the refining marketing unit at Amoco Corp. with responsibility for the capital plan for retail stores including placement, acquisitions and divestitures. Earlier, he worked in refining capital planning and as a research engineer.

Dr. Marshbanks earned his doctorate in chemical engineering from Purdue University, a master of business administration from the University of Chicago, and a bachelor’s degree in chemical engineering from Colorado State University.

Charles Cahn heads Cahn Medical Ventures. In addition to serving as Cylex Inc. board observer, Mr. Cahn is a member of the board of TyRx Pharma Inc., a sustained-release pharmaceutical delivery company; board chairman of MicroMRI Inc., an MRI-based imaging company focused on osteoporosis assessment; and CEO of Calretex LLC, a wound management company.

Previously, he was senior vice president at Sanford C. Bernstein & Co. Inc., an independent research and management company purchased by Alliance Capital Management in 2000. On the board of directors, Mr. Cahn served as senior managing director of the research business after being director of research and a securities analyst.

He serves on the boards of companies invested in by CMV and the advisory board of the Sanford C. Bernstein & Co. Center on Leadership and Ethics at the Columbia Business School. Mr. Cahn also serves on the board of CEI-PEA (Center for Educational Innovation – Public Education Association) and chairs the board of the Cahn Fellows Program for Distinguished New York City Principals at Teachers College, Columbia University.

Mr. Cahn graduated from Washington and Lee University and holds a master of business administration from Columbia University.